Clinical Trial Update: Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of MCLA-129, a bispecific EGFR and cMet antibody, in advanced non-small cell lung cancer and other solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• MCLA-129

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Solid Tumor, Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING